

**Amendments to the Claims/Listing of Claims**

Please cancel claims 12-14 and add new claims 17-19 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

1-9. (Cancelled)

10. (Previously presented) A method of inhibiting the adhesion of integrin expressing cells to vitronectin comprising exposing said cells to contortrostatin or to a biologically active contortrostatin variant so that contortrostatin or said contortrostatin variant binds to the integrin, wherein said contortrostatin variant comprises an amino acid sequence at least 90% identical to amino acid numbers 419 to 483 of SEQ ID NO: 2 as determined by FASTA or BLAST using default opening and gap penalties and a default scoring matrix.

11-14. (Cancelled)

15. (Previously presented) The method of claim 10, wherein said integrin is  $\alpha v\beta 3$  or  $\alpha v\beta 5$ .

16. (Previously presented) The method of claim 10, wherein the cells are exposed to contortrostatin.

17. (New) The method of claim 10, wherein said contortrostatin or said contortrostatin variant (i) binds to integrin  $\alpha v\beta 5$  and (ii) induces  $\alpha v\beta 3$ -mediated tyrosine phosphorylation of CAS and FAK in tumor cells.

18. (New) The method of claim 10, wherein said amino acid sequence is at least 95% identical to amino acid numbers 419 to 483 of SEQ ID NO: 2, as determined by FASTA or BLAST using default opening and gap penalties and a default scoring matrix.

19. (New) The method of claim 10, wherein said contortrostatin or said contortrostatin variant is in the form of a pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier.